Teva And mAbxience Join Forces On Unnamed Oncology Biosimilar
Israeli Firm Continues Partnership Model; mAbxience Aligns With Another Major Firm
Teva continues to find comfort with an ally on biosimilar development, striking a deal with the Fresenius-Kabi-backed mAbxience for an undisclosed oncology biosimilar.
